<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04123262</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-20168</org_study_id>
    <nct_id>NCT04123262</nct_id>
  </id_info>
  <brief_title>Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression</brief_title>
  <official_title>HORMONET: Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lee Moffitt Cancer Center and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, single-stage clinical study of tamoxifen for patients with&#xD;
      well-differentiated neuroendocrine tumors and radiological progression with positive (&gt; 1%)&#xD;
      HR (estrogen and/or progesterone) expression by immunohistochemistry (IHC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>At 24 weeks after start of tamoxifen (at end of cycle 6 - each cycle is 28 days)</time_frame>
    <description>Defined by absence of radiological progression in conventional imaging examinations by RECIST 1.1. Isolated increase of biomarker (chromogranin A) or specific hormone will not be considered progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Defined by time from tamoxifen day 1 cycle 1 to death from any cause or radiological progression by RECIST 1.1, whichever occurs first. Participants alive and without progression at the time of study analysis will be censored for time-to-event analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Biochemical response</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Defined by at least 30 percent drop in the marker (chromogranin and / or specific hormone) at any time of treatment in relation to pre-treatment value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiological response rate</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Assessed by RECIST criteria 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Defined by absence of radiological progression by RECIST 1.1 criteria, according to the intensity of expression by immunohistochemistry (IHC) of HR and also according to primary site (pancreas, gastrointestinal or lung)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-related Adverse Events</measure>
    <time_frame>Through study completion, an average of 5 years</time_frame>
    <description>Frequency of adverse events of grades 2 or more by Common Adverse Event Toxicity Criteria (CTCAE) version 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Progesterone Receptor Positive Tumor</condition>
  <condition>Estrogen Receptor Positive Tumor</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive tamoxifen 20mg orally once daily with a glass of water. Each cycle will be defined for 42 days (6 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen 20 mg</intervention_name>
    <description>Tamoxifen 20mg orally will be given once daily to participants with water</description>
    <arm_group_label>Tamoxifen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of well differentiated NET (typical and atypical lung&#xD;
             carcinoids, NET G1, NET G2 of all gastroenteropancreatic sites and pancreatic NET G3&#xD;
             according to WHO 2017 classification) 20 advanced / metastatic, inoperable, with no&#xD;
             possibility of curative treatment&#xD;
&#xD;
          -  Immunohistochemical expression ≥ 1 percent for estrogen and / or progesterone receptor&#xD;
&#xD;
          -  Disease with radiological progression (at least 10 percent tumor volume growth) in the&#xD;
             last 12 months before day 1 cycle 1.&#xD;
&#xD;
          -  No possibility of established treatments due to lack of access, risk of toxicities or&#xD;
             without clinical indication. Patients who meet criteria for watchful waiting (low-dose&#xD;
             disease and non-functioning NET) may be included.&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  ECOG performance scale 0 to 2.&#xD;
&#xD;
          -  Adequate organic function as defined by the following criteria:&#xD;
&#xD;
               -  serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT) ≤&#xD;
                  2.5 times the upper limit of local laboratory normality (ULN-LL); (up to 5xULN&#xD;
                  for participants with liver metastases)&#xD;
&#xD;
               -  Total serum bilirubin ≤ 2.0 x ULN-LL;&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500 / mm^3;&#xD;
&#xD;
               -  Platelet count ≥ 80,000 / mm^3;&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g / dL;&#xD;
&#xD;
               -  Estimated creatinine clearance by the MDRD equation ≥ 30ml / min&#xD;
&#xD;
          -  Albumin ≥ 3.5 g / dL;&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  Term of free and informed consent signed by the patient or legal representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants already on tamoxifen, but other prior treatment are allowed&#xD;
&#xD;
          -  Participants with aggressive disease requiring cytotoxic therapy or locoregional&#xD;
             therapies (eg hepatic embolization)&#xD;
&#xD;
          -  A history of serious clinical or psychiatric illness that, by clinical judgment, may&#xD;
             involve participation risk in this study&#xD;
&#xD;
          -  Participants participating in other protocols with experimental drugs&#xD;
&#xD;
          -  Participants with oral food difficulties&#xD;
&#xD;
          -  Participants who underwent major recent surgery less than 4 weeks previously&#xD;
&#xD;
          -  Participants receiving chemotherapy or other oncologic therapy for less than 3 weeks&#xD;
&#xD;
          -  Participants who use oral anticoagulation&#xD;
&#xD;
          -  Previous history of deep vein thrombosis or pulmonary embolism in the last 12 months&#xD;
&#xD;
          -  Pregnant or lactating participants&#xD;
&#xD;
          -  Participants with postmenopausal vaginal bleeding with no defined etiology&#xD;
&#xD;
          -  Participants with breast cancer who need to use tamoxifen for this neoplasm&#xD;
&#xD;
          -  Another synchronous neoplasm that requires systemic treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Strosberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moffitt Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Taymeyah Al-Toubah</last_name>
    <phone>(813) 745-6454</phone>
    <email>Taymeyah.Altoubah@Moffitt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taymeyah Al-Toubah</last_name>
      <phone>813-745-6454</phone>
      <email>Taymeyah.Altoubah@Moffitt.org</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Strosberg, MD</last_name>
      <phone>(813) 745-7257</phone>
      <email>Jonathan.Strosberg@Moffitt.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tamoxifen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

